Articles tagged with Antifungal Agents
This systematic review found that both chemical and non-chemical denture cleansers effectively reduce Candida species, with chemical agents demonstrating more consistent antifungal action. Non-chemical agents preserve material integrity and are preferred by patients for their taste and ease of use.
A new diagnostic platform enables rapid and accurate detection of drug-resistant C. auris pathogens using CRISPR technology, allowing for more effective treatment and prevention of hospital outbreaks. The dSHERLOCK test can detect the presence of mutations causing antimicrobial resistance in just 40 minutes.
The book examines antibiotic-induced reproductive toxicity, microbiome alterations, and emerging concerns around antibiotic resistance. It provides critical insights for clinicians, pharmacists, researchers, and students in reproductive medicine and pharmacology.
Researchers have discovered ancestral evolutionary links of Aspergillus latus strains through genome sequencing analyses, revealing potential for reduced susceptibility to antifungal medications. The study highlights the need for improved molecular diagnostic tools to accurately identify A. latus strains and manage aspergillosis.
Researchers discovered that a specific gene duplication in the fungus Madurella fahalii enables it to neutralize medication, leading to effective treatment challenges. This study highlights the potential of molecular techniques to uncover drug resistance mechanisms and pave the way for targeted therapies.
Scientists at the University of Kansas have identified a previously unknown gene cluster responsible for producing sartorypyrones, a chemical made by the fungal pathogen Aspergillus fumigatus. This discovery could lead to new therapies for fungal infections and eco-friendly industrial uses.
Researchers at the University of Illinois have developed a new antifungal molecule that targets fungal cells without harming human kidney cells or other tissues. The molecule, dubbed AM-2-19, has shown significant efficacy against various fungal infections in vitro and in vivo studies.
Researchers have discovered a new way to combat fatal fungal infections by blocking the production of fatty acids, a major component of fats. The breakthrough could lead to more effective treatments against species-resistant fungi.
Researchers discovered that combining brilacidin with two classes of antifungals cleared up lung infections in animals. Brilacidin alone blocked growth of drug-resistant fungal species and developed disease in an animal model of keratitis, a corneal infection affecting millions worldwide.
Researchers at Ben-Gurion University of the Negev discovered a new compound derived from marine red microalga that exhibits effective antimicrobial activity against bacteria and fungus. The compound's unique structure, featuring long and dense spikes, allows it to poke holes in bacterial membranes and kill off infections.
A post-pandemic outbreak of a drug-resistant fungus in Brazil was linked to the misuse of medications and full ICUs. The study found that 90% of infected patients had strains resistant to fluconazole and echinocandins, leading to high mortality rates.
Researchers have identified a new antifungal antibiotic named solanimycin produced by a pathogenic potato bacterium. The compound shows efficacy against various fungi, including Candida albicans, and has potential for both agricultural and clinical applications.
Research from the Francis Crick Institute found that microbial communities with auxotrophs, unable to produce essential metabolites, have increased tolerance to hundreds of drugs. These cells cooperate by absorbing and exchanging metabolites, leading to higher metabolic flow and a richer environment for growth.
UC Riverside scientists developed a technique to map tryptophan production, opening the door to new treatment drugs. By understanding how bacteria make tryptophan, researchers can create enzymes that shut down this process, killing invasive bacterial cells without affecting human cells.
Researchers have mapped the atomic structure of amphotericin B, a powerful but toxic antifungal agent. The detailed structure reveals how the drug kills fungal cells by robbing them of sterol molecules, providing a roadmap for synthesizing less-toxic derivatives.
Researchers studied bicyclic monoterpene alcohols' fungicidal activity against various fungi, finding (−)-myrtenol to be most promising. The compounds also showed antioxidant and membrane-protective activities, suggesting potential practical applications.
A team of Russian chemists has developed a new rhodium catalyst for organic synthesis, enabling the creation of complex molecular frameworks of antifungal agents. The catalyst's asymmetrical design allows for full spatial control over reaction outcomes.
A UC Irvine study reveals that low-dose exposure to the chemical tributyltin during pregnancy can lead to obesity in offspring and great-grandchildren, affecting gene expression and fat accumulation. The findings suggest permanent effects without subsequent exposure, highlighting the risks of endocrine-disrupting compounds.
The American Thoracic Society has released a new statement on the treatment of fungal infections in adult pulmonary and critical care patients, taking into account new medications and treatment approaches. The guidelines cover traditional antifungal agents, newer agents, and rare and emerging fungi.
Dr. Thomas J. Walsh, Director of the Transplantation-Oncology Infectious Diseases Program at Weill Cornell Medical College, has been selected as the 2010 laureate of the sanofi-aventis ICAAC Award for his groundbreaking work on antifungal pharmacology and therapeutics.
The study confirms voriconazole's effectiveness in combating a wide range of fungal infections, including those caused by Candida species. It is also noted that voriconazole exhibits higher potency and spectrum activity compared to itraconazole against yeast species.